Servier Acquires Edgewise Muscular Dystrophy Business for $2.65B
SURESNES, France, June 1, 2026 Servier has announced a landmark agreement to acquire Edgewise Therapeutics’ muscular dystrophy business in...
Neurology
Advertisement
AbbVie Secures EU Approval for AQUIPTA as Acute Migraine Treatment
NORTH CHICAGO, Ill., June 2, 2026 AbbVie has announced that the European Commission (EC) has approved AQUIPTA® (atogepant) for...
Amgen’s IMDYLLTRA Wins EU Approval for Small Cell Lung Cancer
THOUSAND OAKS, Calif., June 1, 2026 Amgen has secured a major regulatory milestone with the European Commission approval of...
NeuroPace Wins FDA Approval for AI-Powered Epilepsy Tool
MOUNTAIN VIEW, Calif., May 29, 2026 NeuroPace, Inc., a leading medical technology company focused on transforming the treatment of...
Merz Therapeutics Unveils New Insights Into Parkinson’s OFF Episodes at WPC 2026
FRANKFURT, Germany & RALEIGH, N.C. — May 28, 2026 Merz Therapeutics presented new research at the World Parkinson Congress...
Advertisements
Ono Pharma Highlights New Phase 2 MSA Data
OSAKA, Japan — May 28, 2026 Ono Pharmaceutical Co., Ltd. announced the presentation of new clinical data from its...
Emalex Ecopipam Phase 3 Tourette Data Published
CHICAGO, Ill., May 26, 2026 Emalex Biosciences announced that Phase 3 clinical data for ecopipam, its investigational dopamine-1 (D1)...
Persistence Market Research Predicts CGRP Inhibitors Market to Reach $12.5B
London, United Kingdom, May 25, 2026 The global market for CGRP inhibitors, one of the fastest-growing classes of migraine...
Teva Uncovers Widespread Underdiagnosis of Tardive Dyskinesia in Young Patients
PARSIPPANY, N.J. and TEL AVIV, Israel, May 18, 2026 Teva Pharmaceuticals has announced new findings from its ongoing IMPACT-TD...
Encoded Therapeutics Reports Strong ETX101 Results
SOUTH SAN FRANCISCO, Calif. – May 13, 2026 Encoded Therapeutics presented expanded clinical data from its ongoing POLARIS Phase...
Advertisement
